Citations

Mayo Clinic

Showing 10 of 108599 citations.

Hepatocyte growth factor demonstrates racial heterogeneity as a biomarker for coronary heart disease
Bielinski, Suzette J. , Berardi, Cecilia , Decker, Paul A. , Bell, Elizabeth J. , Pankow, James S. , Sale, Michèle M. , Tang, Weihong , Hanson, Naomi Q., Wassel, Christina L. , Budoff, Matthew J. , Sicotte, Hugues , Tsai, Michael Y. , de Andrade, Mariza, Decker, Paul A. , Larson, Nicholas B. , Andrade, Mariza de , Polak, Joseph F. , Bielinski, Suzette , Budoff, Matthew , Pankow, James S , Tang, Weihong

Heart | June 1, 2017 | Volume: 103 | Issue: 15 | Pages: 1185-1193

10.1136/heartjnl-2016-310450 | PMID 28572400 Get It

Objective To determine if hepatocyte growth factor (HGF), a promising biomarker of coronary heart disease (CHD) given its release into circulation in response to endothelial damage, is associated with subclinical and clinical CHD in a racial/ethnic diverse population. Methods HGF was measured in 6738 participants of the Multi-Ethnic Study of Atherosclerosis (MESA). Highest mean HGF values (pg/mL) were observed in Hispanic, followed by African, non-Hispanic white, then Chinese Americans. Results In all races/ethnicities, HGF levels were associated with older age, higher systolic blood pressure (SBP) and body mass index, lower high-density lipoprotein, diabetes and current smoking. In fully adjusted models, each SD higher HGF was associated with an average increase in coronary artery calcium (CAC) of 55 Agatston units for non-Hispanic whites (p<0.001) and 51 Agatston units for African-Americans (p=0.007) but was not in the other race/ethnic groups (interaction p=0.02). There were 529 incident CHD events, and CHD risk was 41% higher in African (p<0.001), 17% in non-Hispanic white (p=0.026) and Chinese (p=0.36), and 6% in Hispanic Americans (p=0.56) per SD increase in HGF. Conclusion In a large and diverse population-based cohort, we report that HGF is associated with subclinical and incident CHD. We demonstrate evidence of racial/ethnic heterogeneity within these associations, as the results are most compelling in African-Americans and non-Hispanic white Americans. We provide evidence that HGF is a biomarker of atherosclerotic disease that is independent of traditional risk factors.
Development and validation of a nomogram to estimate the pretest probability of cancer in Chinese patients with solid solitary pulmonary nodules: A multi‐institutional study
She, Yunlang , Zhao, Lilan , Dai, Chenyang , Ren, Yijiu , Jiang, Gening , Xie, Huikang , Zhu, Huiyuan , Sun, Xiwen , Shi, Shunbin, Shi, Weirong, Xie, Dong , Chen, Chang , Yang, Ping , Chen, Yongbing , Yu, Bing

Journal of Surgical Oncology | June 1, 2017 | Volume: 116 | Issue: 6 | Pages: 756-762

10.1002/jso.24704 | PMID 28570780 Get It

ObjectivesTo develop and validate a nomogram to estimate the pretest probability of malignancy in Chinese patients with solid solitary pulmonary nodule (SPN).Materials and MethodsA primary cohort of 1798 patients with pathologically confirmed solid SPNs after surgery was retrospectively studied at five institutions from January 2014 to December 2015. A nomogram based on independent prediction factors of malignant solid SPN was developed. Predictive performance also was evaluated using the calibration curve and the area under the receiver operating characteristic curve (AUC).ResultsThe mean age of the cohort was 58.9 ± 10.7 years. In univariate and multivariate analysis, age; history of cancer; the log base 10 transformations of serum carcinoembryonic antigen value; nodule diameter; the presence of spiculation, pleural indentation, and calcification remained the predictive factors of malignancy. A nomogram was developed, and the AUC value (0.85; 95%CI, 0.83‐0.88) was significantly higher than other three models. The calibration cure showed optimal agreement between the malignant probability as predicted by nomogram and the actual probability.ConclusionsWe developed and validated a nomogram that can estimate the pretest probability of malignant solid SPNs, which can assist clinical physicians to select and interpret the results of subsequent diagnostic tests.
Comparison of the vasodilatory effects of sodium nitroprusside vs. nitroglycerin
Ranadive, Sushant M. , Eugene, Andy R., Nicholson, Wayne T. , Joyner, Michael J. , Ranadive, Sushant M. , Dillon, Gabrielle, Eugene, Andy R., Dillon, Gabrielle A. , Joyner, Michael J , Ranadive, Sushant

Journal of Applied Physiology | June 1, 2017 | Volume: 123 | Issue: 2 | Pages: 402-406

10.1152/japplphysiol.00167.2017 | PMID 28572495 Get It

The vasodilatory mechanism of Nntroglycerin (NTG) is similar to sodium nitroprusside (SNP) in regard to action on guanosine 3′5′-monophosphate (cyclic GMP) via nitric oxide. However, it is unknown whether NTG can achieve the same magnitude of vasodilation in the forearm as SNP. Therefore, the purpose of the study was to evaluate the differences in forearm blood flow (FBF) and forearm vascular conductance (FVC) during escalating infusions of NTG vs. SNP at similar concentration doses and rates. We measured FBF using venous occlusion plethysmography (VOP) and Doppler ultrasound in eight young, healthy participants (mean age = 28 ± 2 yr) during four forearm volume (FAV)-specific doses (0.25, 0.5, 1, and 2 µg·100 ml FAV−1·min−1) of SNP and NTG infused via a brachial artery catheter. There was a significant difference in FVC of SNP vs. NTG only at the higher doses, as measured by VOP (14.9 ± 1.4 and 18.3 ± 1.5 vs. 11.6 ± 1.2 and 12.5 ± 1.2 ml/dl FAV−1·min−1·100 mmHg−1). FVC as measured by Doppler ultrasound unadjusted for FAV was significantly different at the lowest and the higher two doses of SNP compared with NTG (202.1 ± 25.8, 329.4 ± 46.7, and 408 ± 63.5 vs. 142.9 ± 22.4, 217.2 ± 18.8, and 247.5 ± 18.2 ml·min−1·100 mmHg−1). SNP induces significantly higher vasodilatory actions compared with NTG. However, NTG is comparable in eliciting equivalent vasodilator effects to SNP during low concentration doses when measured by VOP. Importantly, for forearm pharmacology studies, NTG can elicit marked endothelium-independent forearm vasodilation. NEW & NOTEWORTHY We compared the vasodilatory capacities of NTG vs. SNP at similar concentration doses and rates into the forearm. Based on the results of the study, it may be feasible to use intra-arterial NTG as a measure of endothelial-independent vasodilator in research studies. However, NTG dosing may need to be higher if used as an endothelial-independent vasodilator due to significant differences in the vasodilatory effects during higher doses of SNP compared with NTG.
MR Elastography Demonstrates Unique Regional Brain Stiffness Patterns in Dementias
ElSheikh, Mona M., Arani, Arvin , Perry, Avital , Meyer, Fredric B. , Savica, Rodolfo , ElSheikh, Mona, Boeve, Bradley F. , Ehman, Richard L. , Huston, John , Arani, Arvin

American Journal of Roentgenology | June 1, 2017 | Volume: 209 | Issue: 2 | Pages: 403-408

10.2214/ajr.16.17455 | PMID 28570101 Get It

Concurrent Electroconvulsive Therapy and Bupropion Treatment
Takala, Christopher R., Leung, Jonathan G. , Murphy, Lauren L., Geske, Jennifer R. , Palmer, Brian A. , Leung, Jonathan G , Geske, Jennifer

The Journal of ECT | June 1, 2017 | Volume: 33 | Issue: 3 | Pages: 185-189

10.1097/yct.0000000000000423 | PMID 28570500 Get It

Background Bupropion is associated with a dose-dependent increased risk of seizures. Use of concomitant bupropion and electroconvulsive therapy (ECT) remains controversial because of an increased risk of prolonged seizures. This is the first systematic evaluation of the effect of bupropion on ECT. Methods A case group (n = 119), patients treated with concomitant ECT and bupropion, was compared with an age and gender frequency–matched control group (n = 261), treated with only ECT. Electroconvulsive therapy treatment data including seizure length, number of treatments, and concurrent medications were extracted. Longitudinal mixed models examined ECT versus ECT + bupropion group differences over the course of treatments measured by seizure duration (electroencephalogram [EEG] and motor). Multivariable models examined the total number of treatments and first and last seizure duration. All models considered group differences with ECT treatment measures adjusted for age, gender, benzodiazepine treatment, lead placement, and setting. Results Electroconvulsive therapy treatment with bupropion led to shorter motor seizure duration (0.047) and EEG seizure duration (P = 0.001). The number of ECT treatments (7.3 vs 7.0 treatments; P = 0.23), respectively, or the probability of a prolonged seizure (P = 0.15) was not significantly different. Benzodiazepine use was significantly more common in control subjects (P = 0.01). Limitations This is a retrospective analysis limited in part by unavailable variables (seizure threshold, nature of EEG and motor seizure monitoring, type of ECT device, dosing and formulation of bupropion, and duration of the current depressive illness). Conclusions This study revealed a significantly shorter duration in seizure length with ECT + concomitant bupropion, but not in the number of required treatments in those treated compared with ECT without bupropion. There remains a critical need to reevaluate the efficacy of concomitant use of psychotropic medications + ECT.
Systematic Review of the Outcomes of Surgical Treatment of Prostate Metastases to the Spine
Molina, Camilo A. , Fourney, Daryl R. , Fisher, Charles G. , Gokaslan, Ziya L. , Schmidt, Meic H. , Rhines, Laurence D. , Fehlings, Michael G. , Laufer, Ilya , Patel, Shreyaskumar , Rampersaud, Y. Raja , Reynolds, Jeremy , Chou, Dean , Mendel, Ehud , Weber, Michael H. , Sciubba, Daniel M. , Reynolds, Jeremy , Clarke, Michelle J. , Bettegowda, Chetan , Fehlings, Michael G , Reynolds, Jeremy

Global Spine Journal | June 1, 2017 | Volume: 7 | Issue: 5 | Pages: 460-468

10.1177/2192568217710911 | PMID 28811991 Get It

Study Design: Systematic review. Objective: Surgical decompression and reconstruction of symptomatic spinal metastases has improved the quality of life in cancer patients. However, most data has been collected on cohorts of patients with mixed tumor histopathology. We systematically reviewed the literature for prognostic factors specific to the surgical treatment of prostate metastases to the spine. Methods: A systemic review of the literature was conducted to answer the following questions: Question 1. Describe the survival and functional outcomes of surgery or vertebral augmentation for prostate metastases to the spine. Question 2. Determine whether overall tumor burden, Gleason score, preoperative functional markers, and hormonal naivety favor operative intervention. Question 3. Establish whether clinical outcomes vary with the evolution of operative techniques. Results: A total of 16 studies met the preset inclusion criteria. All included studies were retrospective series with a level of evidence of IV. Included studies consistently showed a large effect of hormone-naivety on overall survival. Additionally, studies consistently demonstrated an improvement in motor function and the ability to maintain/regain ambulation following surgery resulting in moderate strength of recommendation. All other parameters were of insufficient or low strength. Conclusions: There is a dearth of literature regarding the surgical treatment of prostate metastases to the spine, which represents an opportunity for future research. Based on existing evidence, it appears that the surgical treatment of prostate metastases to the spine has consistently favorable results. While no consistent preoperative indicators favor nonoperative treatment, hormone-naivety and high Karnofsky performance scores have positive effects on survival and clinical outcomes.
Zebrafish and the Cancer Moonshot
Schimmenti, Lisa A. , Schimmenti, Lisa A

Zebrafish | June 1, 2017 | Volume: 14 | Issue: 4 | Pages: 390-392

10.1089/zeb.2017.1450 | PMID 28570143 Get It

A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis
Lu, Calvin, Pappas, George P., Dilling, Daniel F. , Shifren, Adrian , Veeraraghavan, Srihari , Chapman, Jeffrey T., Parambil, Joseph G. , Ruoss, Stephen J. , Young, Lisa R. , Kopras, Elizabeth J. , Roads, Tammy, Krischer, Jeffrey P. , McCormack, Francis X. , McCormack, Francis X , Lu, Calvin, Lee, Hye Seung , Burger, Charles D. , Hammes, Stephen R.

Annals of the American Thoracic Society | June 1, 2017 | Volume: 14 | Issue: 6 | Pages: 919-928

10.1513/annalsats.201610-824oc | PMID 28570161 Get It

Abstract Rationale Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women and can worsen with pregnancy, estrogen treatment, and the menstrual cycle, suggesting an important role for estrogen in disease pathogenesis. Objectives To assess the efficacy and safety of the aromatase inhibitor letrozole in the treatment of LAM. Methods Seventeen postmenopausal women with LAM were enrolled in this phase II trial and randomized to receive letrozole 2.5 mg daily (n = 9) or placebo (n = 8) for a period of 12 months. Five patients in each group were also taking sirolimus at baseline and remained on the drug throughout the treatment period. Lung function, exercise capacity, quality of life, and serum vascular endothelial growth factor D (VEGF-D) were measured at baseline and at 3-month intervals. Results Fifteen patients completed the study. Two patients withdrew. There were no differences in adverse events in the letrozole and placebo groups. The target enrollment of 25 patients per arm was not met, so the efficacy of letrozole could not be assessed as planned. After adjusting for sirolimus use, we found that the rate of change in FEV1 for all subjects was −3 ± 3 ml/mo (P = 0.4), and for serum VEGF-D, the rate of change was −0.024 ± 0.009 pg/ml/mo (P = 0.015), showing a steeper decline in the letrozole group (−0.029 ± 0.013; P = 0.025). All patients who were taking sirolimus had a reduction in VEGF-D levels from baseline to the last visit, compared with only half of the patients who were not taking sirolimus. In a post hoc analysis, eight matched letrozole-treated–placebo-treated pairs were constructed, six of which demonstrated better FEV1 improvement for the letrozole-treated patients. Conclusions Letrozole treatment appears to be safe and well tolerated in postmenopausal patients with LAM, including those taking sirolimus. Enrollment in this trial was compromised by the publication of an effective treatment (sirolimus) in the same month as the study opened, resulting in limited power to detect treatment effects. Post hoc matched pairs exploration studies provide tentative support for additional studies of letrozole in LAM. Considering the reduced rate of lung function decline in postmenopausal patients, future studies will likely require enhanced study designs, such as selective enrollment of those with prognostic biomarkers predictive of decline. Clinical trial registered with www.clinicaltrials.gov (NCT01353209).
Zinc deficiency primes the lung for ventilator-induced injury
Boudreault, Francis, Pinilla-Vera, Miguel , Englert, Joshua A. , Kho, Alvin T. , Isabelle, Colleen , Arciniegas, Antonio J. , Barragan-Bradford, Diana, Quintana, Carolina, Amador-Muñoz, Diana , Guan, Jiazhen, Choi, Kyoung Moo , Registry, MICU, Sholl, Lynette M. , Hurwitz, Shelley, Tschumperlin, Daniel J. , Baron, Rebecca M. , Registry, MICU

JCI Insight | June 1, 2017 | Volume: 2 | Issue: 11 | Pages: No page available

10.1172/jci.insight.86507 | PMID 28570269 Get It

Mechanical ventilation is necessary to support patients with acute lung injury, but also exacerbates injury through mechanical stress–activated signaling pathways. We show that stretch applied to cultured human cells, and to mouse lungs in vivo, induces robust expression of metallothionein, a potent antioxidant and cytoprotective molecule critical for cellular zinc homeostasis. Furthermore, genetic deficiency of murine metallothionein genes exacerbated lung injury caused by high tidal volume mechanical ventilation, identifying an adaptive role for these genes in limiting lung injury. Stretch induction of metallothionein required zinc and the zinc-binding transcription factor MTF1. We further show that mouse dietary zinc deficiency potentiates ventilator-induced lung injury, and that plasma zinc levels are significantly reduced in human patients who go on to develop acute respiratory distress syndrome (ARDS) compared with healthy and non-ARDS intensive care unit (ICU) controls, as well as with other ICU patients without ARDS. Taken together, our findings identify a potentially novel adaptive response of the lung to stretch and a critical role for zinc in defining the lung’s tolerance for mechanical ventilation. These results demonstrate that failure of stretch-adaptive responses play an important role in exacerbating mechanical ventilator–induced lung injury, and identify zinc and metallothionein as targets for lung-protective interventions in patients requiring mechanical ventilation.
Effect of Obstructive Sleep Apnea Treatment on Lipids in Obese Children
Amini, Zarlasht, Kotagal, Suresh , Lohse, Christine M. , Lloyd, Robin M. , Sriram, Swetha, Kumar, Seema , Lohse, Christine, Lloyd, Robin, Kumar, Seema

Children | June 1, 2017 | Volume: 4 | Issue: 6 | Pages: 44

10.3390/children4060044 | PMID 28587180 Get It

Obesity in children is associated with several co-morbidities including dyslipidemia. Obstructive sleep apnea (OSA) is commonly seen in obese children. In adults, diagnosis of OSA independent of obesity is associated with cardiometabolic risk factors including dyslipidemia. There is limited data on the impact of treatment of OSA on lipids in children. The objective of the study was to examine the impact of treatment of OSA on lipids in 24 obese children. Methods: Seventeen children were treated with continuous positive airway pressure (CPAP) and five underwent adenotonsillectomy. Mean apnea hypopnea index prior to treatment was 13.0 + 12.1 and mean body mass index (BMI) was 38.0 + 10.6 kg/m2. Results: Treatment of OSA was associated with improvement in total cholesterol (mean change = −11 mg/dL, p < 0.001), and low-density lipoprotein cholesterol (mean change = –8.8 mg/dL, p = 0.021). Conclusion: Obese children should be routinely screened for OSA, as treatment of OSA favorably influences lipids and therefore decreases their cardiovascular risk.